Journal article
Abstract C097: Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma
Abstract
Abstract Background: MYC-amplified group 3 (G3) medulloblastoma (MB) represents a clinically aggressive subgroup of MB that is defined by leptomeningeal metastases, disease recurrence and particularly poor survivorship in comparison to other MB subgroups. There is an urgent need for a more thorough molecular understanding of G3 MB to develop more effective therapeutic modalities that will improve the durability of remission. Methods: We mapped …
Authors
Singh S; Gwynne W; Suk Y; Chan J; Qualie A; Escudero L; Brown K; Venugopal C; Moffat J; Montenegro-Burke R
Journal
Molecular Cancer Therapeutics, Vol. 22, No. 12_Supplement, pp. c097–c097
Publisher
American Association for Cancer Research (AACR)
Publication Date
December 1, 2023
DOI
10.1158/1535-7163.targ-23-c097
ISSN
1535-7163